351 related articles for article (PubMed ID: 24737137)
1. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
[TBL] [Abstract][Full Text] [Related]
3. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
4. ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter.
Phuan PW; Veit G; Tan JA; Roldan A; Finkbeiner WE; Haggie PM; Lukacs GL; Verkman AS
SLAS Discov; 2018 Sep; 23(8):823-831. PubMed ID: 29533733
[TBL] [Abstract][Full Text] [Related]
5. Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome.
Liu Q; Sabirzhanova I; Yanda MK; Bergbower EAS; Boinot C; Guggino WB; Cebotaru L
J Cyst Fibros; 2018 Sep; 17(5):582-594. PubMed ID: 29936070
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
[TBL] [Abstract][Full Text] [Related]
8. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
9. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
Laselva O; Molinski S; Casavola V; Bear CE
Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
[TBL] [Abstract][Full Text] [Related]
10. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
11. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222.
Singh AK; Fan Y; Balut C; Alani S; Manelli AM; Swensen AM; Jia Y; Neelands TR; Vortherms TA; Liu B; Searle XB; Wang X; Gao W; Hwang TC; Ren HY; Cyr D; Kym PR; Conrath K; Tse C
J Pharmacol Exp Ther; 2020 Jan; 372(1):107-118. PubMed ID: 31732698
[TBL] [Abstract][Full Text] [Related]
12. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
14. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.
Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z
FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.
Odolczyk N; Fritsch J; Norez C; Servel N; da Cunha MF; Bitam S; Kupniewska A; Wiszniewski L; Colas J; Tarnowski K; Tondelier D; Roldan A; Saussereau EL; Melin-Heschel P; Wieczorek G; Lukacs GL; Dadlez M; Faure G; Herrmann H; Ollero M; Becq F; Zielenkiewicz P; Edelman A
EMBO Mol Med; 2013 Oct; 5(10):1484-501. PubMed ID: 23982976
[TBL] [Abstract][Full Text] [Related]
16. Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel.
Renda M; Barreca M; Borrelli A; Spanò V; Montalbano A; Raimondi MV; Bivacqua R; Musante I; Scudieri P; Guidone D; Buccirossi M; Genovese M; Venturini A; Bandiera T; Barraja P; Galietta LJV
Sci Rep; 2023 May; 13(1):7604. PubMed ID: 37165082
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
[TBL] [Abstract][Full Text] [Related]
18. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
19. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
[TBL] [Abstract][Full Text] [Related]
20. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
